Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: Evaluation of CEA-based cancer vaccines

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 576, Issue 1-2, 2005, Pages 132-154

  Hance, Kenneth W ^a   Zeytin, Hasan E ^a   Greiner, John W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Carcinoembryonic antigen; Gastrointestinal cancer; Poxvirus cancer vaccines

Indexed keywords

ACETYLSALICYLIC ACID; BETA CATENIN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CELECOXIB; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; TRANSFORMING GROWTH FACTOR; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; COLORECTAL CANCER; GASTROINTESTINAL TUMOR; GENE EXPRESSION; HUMAN; IMMUNOLOGICAL TOLERANCE; INTESTINE TUMOR; MISMATCH REPAIR; MULTIGENE FAMILY; NONHUMAN; ONCOGENE C MYC; ONCOGENE K RAS; PANCREAS CANCER; POXVIRUS; PRIORITY JOURNAL; REVIEW; SIMIAN VIRUS 40; TRANSGENE; VACCINATION;

ANIMALS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; SURVIVAL RATE;

POXVIRIDAE;

EID: 22144436297     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2004.10.014     Document Type: Review

References (130)

1. H. Sikorska, J. Shuster, and P. Gold Clinical applications of carcinoembryonic antigen Cancer Detect. Prev. 12 1988 321 355
2. S. Oikawa, H. Nakazato, and G. Kosaki Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence Biochem. Biophys. Res. Commun. 142 1987 511 518
3. N. Beauchemin, S. Benchimol, D. Cournoyer, A. Fuks, and C.P. Stanners Isolation and characterization of full-length functional cDNA clones for human carcinoembryonic antigen Mol. Cell Biol. 7 1987 3221 3230
4. J.A. Thompson, F. Grunert, and W. Zimmermann Carcinoembryonic antigen gene family: molecular biology and clinical perspectives J. Clin. Lab. Anal. 5 1991 344 366
5. A. Olsen, S. Teglund, D. Nelson, L. Gordon, A. Copeland, A. Georgescu, A. Carrano, and S. Hammarstrom Gene organization of the pregnancy-specific glycoprotein region on human chromosome 19: assembly and analysis of a 700-kb cosmid contig spanning the region Genomics 23 1994 659 668
6. N. Beauchemin, P. Draber, G. Dveksler, P. Gold, S. Gray-Owen, F. Grunert, S. Hammarstrom, K.V. Holmes, A. Karlsson, M. Kuroki, S.H. Lin, L. Lucka, S.M. Najjar, M. Neumaier, B. Obrink, J.E. Shively, K.M. Skubitz, C.P. Stanners, P. Thomas, J.A. Thompson, M. Virji, S. von Kleist, C. Wagener, S. Watt, and W. Zimmermann Redefined nomenclature for members of the carcinoembryonic antigen family Exp. Cell Res. 252 1999 243 249
7. S. Hammarstrom The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues Semin. Cancer Biol. 9 1999 67 81
8. Dehio, Christoph, Gray-Owen, D. Scott, and T.F. Meyer The role of neisserial Opa proteins in interactions with host cells Trends Microbiol. 6 1998 489 495
9. S. Benchimol, A. Fuks, S. Jothy, N. Beauchemin, K. Shirota, and C.P. Stanners Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule Cell 57 1989 327 334
10. S. Oikawa, C. Inuzuka, M. Kuroki, Y. Matsuoka, G. Kosaki, and H. Nakazato Cell adhesion activity of non-specific cross-reacting antigen (NCA) and carcinoembryonic antigen (CEA) expressed on CHO cell surface: homophilic and heterophilic adhesion Biochem. Biophys. Res. Commun. 164 1989 39 45
11. C.N. Berger, O. Billker, T.F. Meyer, A.L. Servin, and I. Kansau Differential recognition of members of the carcinoembryonic antigen family by Afa/Dr adhesins of diffusely adhering Escherichia coli (Afa/Dr DAEC) Mol. Microbiol. 52 2004 963 983
12. R.B. Hostetter, L.B. Augustus, R. Mankarious, K.F. Chi, D. Fan, C. Toth, P. Thomas, and J.M. Jessup Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis J. Natl. Cancer Inst. 82 1990 380 385
13. A.H. Chevinsky CEA in tumors of other than colorectal origin Semin. Surg. Oncol. 7 1991 162 166
14. T. Hasegawa, K. Isobe, Y. Tsuchiya, S. Oikawa, H. Nakazato, H. Ikezawa, I. Nakashima, and K. Shimokata Establishment and characterisation of human carcinoembryonic antigen transgenic mice Br. J. Cancer 64 1991 710 714
15. C.H. Chan, and C.P. Stanners Novel mouse model for carcinoembryonic antigen-based therapy Mol. Ther. 9 2004 775 785
16. A.M. Eades-Perner, H. van der Putten, A. Hirth, J. Thompson, M. Neumaier, S. von Kleist, and W. Zimmermann Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern Cancer Res. 54 1994 4169 4176
17. P. Clarke, J. Mann, J.F. Simpson, K. Rickard-Dickson, and F.J. Primus Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy Cancer Res. 58 1998 1469 1477
18. L.J. Hefta, H. Schrewe, J.A. Thompson, S. Oikawa, H. Nakazato, and J.E. Shively Expression of complementary DNA and genomic clones for carcinoembryonic antigen and nonspecific cross-reacting antigen in Chinese hamster ovary and mouse fibroblast cells and characterization of the membrane-expressed products Cancer Res. 50 1990 2397 2403
19. J.A. Thompson, A.M. Eades-Perner, M. Ditter, W.J. Muller, and W. Zimmermann Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: an animal model for CEA-directed tumor immunotherapy Int. J. Cancer 72 1997 197 202
20. E. Kass, J. Schlom, J. Thompson, F. Guadagni, P. Graziano, and J.W. Greiner Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus Cancer Res. 59 1999 676 683
21. K.W. Kinzler, M.C. Nilbert, L.K. Su, B. Vogelstein, T.M. Bryan, D.B. Levy, K.J. Smith, A.C. Preisinger, P. Hedge, and D. McKechnie Identification of FAP locus genes from chromosome 5q21 Science 253 1991 661 665
22. J. Groden, A. Thliveris, W. Samowitz, M. Carlson, L. Gelbert, H. Albertsen, G. Joslyn, J. Stevens, L. Spirio, and M. Robertson Identification and characterization of the familial adenomatous polyposis coli gene Cell 66 1991 589 600
23. P. Peltomaki Deficient DNA mismatch repair: a common etiologic factor for colon cancer Hum. Mol. Genet. 10 2001 735 740
24. P. Peltomaki DNA mismatch repair and cancer Mutat. Res. 488 2001 77 85
25. G.P. Boivin, K. Washington, K. Yang, J.M. Ward, T.P. Pretlow, R. Russell, D.G. Besselsen, V.L. Godfrey, T. Doetschman, W.F. Dove, H.C. Pitot, R.B. Halberg, S.H. Itzkowitz, J. Groden, and R.J. Coffey Pathology of mouse models of intestinal cancer: consensus report and recommendations Gastroenterology 124 2003 762 777
26. A.R. Moser, A.R. Shoemaker, C.S. Connelly, L. Clipson, K.A. Gould, C. Luongo, W.F. Dove, P.H. Siggers, and R.L. Gardner Homozygosity for the Min allele of Apc results in disruption of mouse development prior to gastrulation Dev. Dyn. 203 1995 422 433
27. T.C. He, A.B. Sparks, C. Rago, H. Hermeking, L. Zawel, L.T. da Costa, P.J. Morin, B. Vogelstein, and K.W. Kinzler Identification of c-MYC as a target of the APC pathway Science 281 1998 1509 1512
28. O. Tetsu, and F. McCormick Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells Nature 398 1999 422 426
29. A.R. Moser, H.C. Pitot, and W.F. Dove A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse Science 247 1990 322 324
30. A.R. Moser, W.F. Dove, K.A. Roth, and J.I. Gordon The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system J. Cell Biol. 116 1992 1517 1526
31. R. Fodde, W. Edelmann, K. Yang, C. van Leeuwen, C. Carlson, B. Renault, C. Breukel, E. Alt, M. Lipkin, and P.M. Khan A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors Proc. Natl. Acad. Sci. U.S.A. 91 1994 8969 8973
32. R. Smits, A. Kartheuser, S. Jagmohan-Changur, V. Leblanc, C. Breukel, A. de Vries, H. van Kranen, J.H. van Krieken, S. Williamson, W. Edelmann, R. Kucherlapati, P.M. Khan, and R. Fodde Loss of Apc and the entire chromosome 18 but absence of mutations at the Ras and Tp53 genes in intestinal tumors from Apc1638N, a mouse model for Apc-driven carcinogenesis Carcinogenesis 18 1997 321 327
33. M. Oshima, H. Oshima, K. Kitagawa, M. Kobayashi, C. Itakura, and M. Taketo Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene Proc. Natl. Acad. Sci. U.S.A. 92 1995 4482 4486
34. C.F. Quesada, H. Kimata, M. Mori, M. Nishimura, T. Tsuneyoshi, and S. Baba Piroxicam and acarbose as chemopreventive agents for spontaneous intestinal adenomas in APC gene 1309 knockout mice Jpn. J. Cancer Res. 89 1998 392 396
35. T.P. Pretlow, W. Edelmann, R. Kucherlapati, T.G. Pretlow, and L.H. Augenlicht Spontaneous aberrant crypt foci in Apc1638N mice with a mutant Apc allele Am. J. Pathol. 163 2003 1757 1763
36. W. Edelmann, K. Yang, M. Kuraguchi, J. Heyer, M. Lia, B. Kneitz, K. Fan, A.M. Brown, M. Lipkin, and R. Kucherlapati Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice Cancer Res. 59 1999 1301 1307
37. J.W. Greiner, H. Zeytin, M.R. Anver, and J. Schlom Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity Cancer Res. 62 2002 6944 6951
38. H.E. Zeytin, A.C. Patel, C.J. Rogers, D. Canter, S.D. Hursting, J. Schlom, and J.W. Greiner Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice Cancer Res. 64 2004 3668 3678
39. B. Romagnolo, D. Berrebi, S. Saadi-Keddoucci, A. Porteu, A. Pichard, M. Peuchmaur, A. Vandewalle, A. Kahn, and C. Perret Intestinal dysplasia and adenoma in transgenic mice after overexpression of an activated B-catenin Cancer Res. 59 1999 3875 3879
40. M.H. Wong, B. Rubinfeld, and J.I. Gordon Effects of forced expression of an NH2-terminal truncated beta-Catenin on mouse intestinal epithelial homeostasis J. Cell Biol. 141 1998 765 777
41. N. Harada, Y. Tamai, T. Ishikawa, B. Sauer, K. Takaku, M. Oshima, and M.M. Taketo Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene EMBO J. 18 1999 5931 5942
42. A.H. Reitmair, M. Redston, J.C. Cai, T.C. Chuang, M. Bjerknes, H. Cheng, K. Hay, S. Gallinger, B. Bapat, and T.W. Mak Spontaneous intestinal carcinomas and skin neoplasms in Msh2-deficient mice Cancer Res. 56 1996 3842 3849
43. W. Edelmann, A. Umar, K. Yang, J. Heyer, M. Kucherlapati, M. Lia, B. Kneitz, E. Avdievich, K. Fan, E. Wong, G. Crouse, T. Kunkel, M. Lipkin, R.D. Kolodner, and R. Kucherlapati The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression Cancer Res. 60 2000 803 807
44. A.R. Shoemaker, K.M. Haigis, S.M. Baker, S. Dudley, R.M. Liskay, and W.F. Dove Mlh1 deficiency enhances several phenotypes of Apc(Min)/+ mice Oncogene 19 2000 2774 2779
45. M. Kuraguchi, K. Yang, E. Wong, E. Avdievich, K. Fan, R.D. Kolodner, M. Lipkin, A.M. Brown, R. Kucherlapati, and W. Edelmann The distinct spectra of tumor-associated Apc mutations in mismatch repair-deficient Apc1638N mice define the roles of MSH3 and MSH6 in DNA repair and intestinal tumorigenesis Cancer Res. 61 2001 7934 7942
46. S. Markowitz, J. Wang, L. Myeroff, R. Parsons, L. Sun, J. Lutterbaugh, R.S. Fan, E. Zborowska, K.W. Kinzler, and B. Vogelstein Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability Science 268 1995 1336 1338
47. R. Parsons, L.L. Myeroff, B. Liu, J.K. Willson, S.D. Markowitz, K.W. Kinzler, and B. Vogelstein Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer Cancer Res. 55 1995 5548 5550
48. Y. Akiyama, H. Nakasaki, Z. Nihei, T. Iwama, T. Nomizu, J. Utsunomiya, and Y. Yuasa Frequent microsatellite instabilities and analyses of the related genes in familial gastric cancers Jpn. J. Cancer Res. 87 1996 595 601
49. M.M. Shull, I. Ormsby, A.B. Kier, S. Pawlowski, R.J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, and D. Calvin Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease Nature 359 1992 693 699
50. A.B. Kulkarni, C.G. Huh, D. Becker, A. Geiser, M. Lyght, K.C. Flanders, A.B. Roberts, M.B. Sporn, J.M. Ward, and S. Karlsson Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death Proc. Natl. Acad. Sci. U.S.A. 90 1993 770 774
51. S.J. Engle, J.B. Hoying, G.P. Boivin, I. Ormsby, P.S. Gartside, and T. Doetschman Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis Cancer Res. 59 1999 3379 3386
52. S.J. Engle, I. Ormsby, S. Pawlowski, G.P. Boivin, J. Croft, E. Balish, and T. Doetschman Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice Cancer Res. 62 2002 6362 6366
53. K. Eppert, S.W. Scherer, H. Ozcelik, R. Pirone, P. Hoodless, H. Kim, L.C. Tsui, B. Bapat, S. Gallinger, I.L. Andrulis, G.H. Thomsen, J.L. Wrana, and L. Attisano MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma Cell 86 1996 543 552
54. S. Thiagalingam, C. Lengauer, F.S. Leach, M. Schutte, S.A. Hahn, J. Overhauser, J.K. Willson, S. Markowitz, S.R. Hamilton, S.E. Kern, K.W. Kinzler, and B. Vogelstein Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers Nat. Genet. 13 1996 343 346
55. Y. Takagi, H. Kohmura, M. Futamura, H. Kida, H. Tanemura, K. Shimokawa, and S. Saji Somatic alterations of the DPC4 gene in human colorectal cancers in vivo Gastroenterology 111 1996 1369 1372
56. W.R. Waldrip, E.K. Bikoff, P.A. Hoodless, J.L. Wrana, and E.J. Robertson Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo Cell 92 1998 797 808
57. Y. Zhu, J.A. Richardson, L.F. Parada, and J.M. Graff Smad3 mutant mice develop metastatic colorectal cancer Cell 94 1998 703 714
58. M.M. Taketo, and K. Takaku Gastro-intestinal tumorigenesis in Smad4 mutant mice Cytokine Growth Factor Rev. 11 2000 147 157
59. A.L. Cubilla, and P.J. Fitzgerald Morphological patterns of primary nonendocrine human pancreas carcinoma Cancer Res. 35 1975 2234 2248
60. D.H. Berger, H. Chang, M. Wood, L. Huang, C.W. Heath, T. Lehman, and B.A. Ruggeri Mutational activation of K-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking status Cancer 85 1999 326 332
61. D.J. Brat, K.D. Lillemoe, C.J. Yeo, P.B. Warfield, and R.H. Hruban Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas Am. J. Surg. Pathol. 22 1998 163 169
62. R.H. Hruban, C.J. Yeo, and S.E. Kern Pancreatic Cancer B. Vogelstein K.W. Kinzler The Genetic Basis of Human Cancer 2002 McGraw-Hill New York 659 673
63. N. Bardeesy, N.E. Sharpless, R.A. DePinho, and G. Merlino The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model Semin. Cancer Biol. 11 2001 201 218
64. D.M. Ornitz, R.E. Hammer, A. Messing, R.D. Palmiter, and R.L. Brinster Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice Science 238 1987 188 193
65. M.J. Tevethia, R.H. Bonneau, J.W. Griffith, and L. Mylin A simian virus 40 large T-antigen segment containing amino acids 1 to 127 and expressed under the control of the rat elastase-1 promoter produces pancreatic acinar carcinomas in transgenic mice J. Virol. 71 1997 8157 8166
66. H.L. Kaufman, J. Di Vito Jr., and H. Horig Immunotherapy for pancreatic cancer: current concepts Hematol. Oncol. Clin. North Am. 16 2002 159 197 viii
67. P. Mukherjee, A.R. Ginardi, C.S. Madsen, C.J. Sterner, M.C. Adriance, M.J. Tevethia, and S.J. Gendler Mice with spontaneous pancreatic cancer naturally develo MUC-1-specific CTLs that eradicate tumors when adoptively transferred J. Immunol. 165 2000 3451 3460
68. E.J. McConnell, L.B. Pathangey, C.S. Madsen, S.J. Gendler, and P. Mukherjee Dendritic cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor model J. Surg. Res. 107 2002 196 202
69. E.P. Sandgren, C.J. Quaife, A.G. Paulovich, R.D. Palmiter, and R.L. Brinster Pancreatic tumor pathogenesis reflects the causative genetic lesion Proc. Natl. Acad. Sci. U.S.A. 88 1991 93 97
70. E.P. Sandgren, N.C. Luetteke, R.D. Palmiter, R.L. Brinster, and D.C. Lee Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast Cell 61 1990 1121 1135
71. M. Wagner, H. Luhrs, G. Kloppel, G. Adler, and R.M. Schmid Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice Gastroenterology 115 1998 1254 1262
72. M. Wagner, F.R. Greten, C.K. Weber, S. Koschnick, T. Mattfeldt, W. Deppert, H. Kern, G. Adler, and R.M. Schmid A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease Genes Dev. 15 2001 286 293
73. A.J. Aguirre, N. Bardeesy, M. Sinha, L. Lopez, D.A. Tuveson, J. Horner, M.S. Redston, and R.A. DePinho Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma Genes Dev. 17 2003 3112 3126
74. N. Bardeesy, and R.A. DePinho Pancreatic cancer biology and genetics Nat. Rev. Cancer 2 2002 897 909
75. J.W. Hodge, J.P. McLaughlin, J.A. Kantor, and J. Schlom Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T cell immunity and antitumor responses Vaccine 15 1997 759 768
76. J.P. McLaughlin, S. Abrams, J. Kantor, M.J. Dobrzanski, J. Greenbaum, J. Schlom, and J.W. Greiner Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity J. Immunother. 20 1997 449 459
77. J.W. Hodge, H. Sabzevari, A.G. Yafal, L. Gritz, M.G. Lorenz, and J. Schlom A triad of costimulatory molecules synergize to amplify T cell activation Cancer Res. 59 1999 5800 5807
78. P.J. Morrissey, L. Bressler, L.S. Park, A. Alpert, and S. Gillis Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells J. Immunol. 139 1987 1113 1119
79. M.L. Disis, H. Bernhard, F.M. Shiota, S.L. Hand, J.R. Gralow, E.S. Huseby, S. Gillis, and M.A. Cheever Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines Blood 88 1996 202 210
80. E. Kass, J. Parker, J. Schlom, and J.W. Greiner Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen-presenting cells in regional lymph nodes Cytokine 12 2000 960 971
81. V. Bronte, D.B. Chappell, E. Apolloni, A. Cabrelle, M. Wang, P. Hwu, and N.P. Restifo Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation J. Immunol. 162 1999 5728 5737
82. E. Kass, D.L. Panicali, G. Mazzara, J. Schlom, and J.W. Greiner Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant Cancer Res. 61 2001 206 214
83. J.E. Paulsen, I.L. Steffensen, E.M. Loberg, T. Husoy, E. Namork, and J. Alexander Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon Cancer Res. 61 2001 5010 5015
84. W.L. Smith, R.M. Garavito, and D.L. DeWitt Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2 J. Biol. Chem. 271 1996 33157 33160
85. J.L. Masferrer, K. Seibert, B. Zweifel, and P. Needleman Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme Proc. Natl. Acad. Sci. U.S.A. 89 1992 3917 3921
86. D.A. Kujubu, B.S. Fletcher, B.C. Varnum, R.W. Lim, and H.R. Herschman TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue J. Biol. Chem. 266 1991 12866 12872
87. R.F. Souza, K. Shewmake, D.G. Beer, B. Cryer, and S.J. Spechler Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells Cancer Res. 60 2000 5767 5772
88. J.R. Vane Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat. New Biol. 231 1971 232 235
89. W.E. Smalley, and R.N. DuBois Colorectal cancer and nonsteroidal anti-inflammatory drugs Adv. Pharmacol. 39 1997 1 20
90. R.S. Sandler, S. Halabi, J.A. Baron, S. Budinger, E. Paskett, R. Keresztes, N. Petrelli, J.M. Pipas, D.D. Karp, C.L. Loprinzi, G. Steinbach, and R. Schilsky A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer N. Engl. J. Med. 348 2003 883 890
91. J.A. Baron, B.F. Cole, R.S. Sandler, R.W. Haile, D. Ahnen, R. Bresalier, G. McKeown-Eyssen, R.W. Summers, R. Rothstein, C.A. Burke, D.C. Snover, T.R. Church, J.I. Allen, M. Beach, G.J. Beck, J.H. Bond, T. Byers, E.R. Greenberg, J.S. Mandel, N. Marcon, L.A. Mott, L. Pearson, F. Saibil, and R.U. van Stolk A randomized trial of aspirin to prevent colorectal adenomas N. Engl. J. Med. 348 2003 891 899
92. M. Cruz-Correa, L.M. Hylind, K.E. Romans, S.V. Booker, and F.M. Giardiello Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study Gastroenterology 122 2002 641 645
93. M.M. Wolfe, D.R. Lichtenstein, and G. Singh Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs N. Engl. J. Med. 340 1999 1888 1899
94. A.T. Koki, K.M. Leahy, and J.L. Masferrer Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy Expert. Opin. Investig. Drugs 8 1999 1623 1638
95. E. Fosslien Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia Crit Rev. Clin. Lab Sci. 37 2000 431 502
96. J.L. Masferrer, K.M. Leahy, A.T. Koki, B.S. Zweifel, S.L. Settle, B.M. Woerner, D.A. Edwards, A.G. Flickinger, R.J. Moore, and K. Seibert Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors Cancer Res. 60 2000 1306 1311
97. M. Oshima, J.E. Dinchuk, S.L. Kargman, H. Oshima, B. Hancock, E. Kwong, J.M. Trzaskos, J.F. Evans, and M.M. Taketo Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 87 1996 803 809
98. B.S. Reddy, Y. Hirose, R. Lubet, V. Steele, G. Kelloff, S. Paulson, K. Seibert, and C.V. Rao Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis Cancer Res. 60 2000 293 297
99. M. Oshima, N. Murai, S. Kargman, M. Arguello, P. Luk, E. Kwong, M.M. Taketo, and J.F. Evans Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor Cancer Res. 61 2001 1733 1740
100. R.F. Jacoby, K. Seibert, C.E. Cole, G. Kelloff, and R.A. Lubet The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis Cancer Res. 60 2000 5040 5044
101. G. Steinbach, P.M. Lynch, R.K. Phillips, M.H. Wallace, E. Hawk, G.B. Gordon, N. Wakabayashi, B. Saunders, Y. Shen, T. Fujimura, L.K. Su, and B. Levin The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N. Engl. J. Med. 342 2000 1946 1952
102. M.A. Iniguez, C. Punzon, and M. Fresno Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors J. Immunol. 163 1999 111 119
103. M. Rivero, B. Santiago, M. Galindo, M.T. Brehmer, and J.L. Pablos Cyclooxygenase-2 inhibition lacks immunomodulatory effects on T cells Clin. Exp. Rheumatol. 20 2002 379 385
104. S.D. Goodwin, and R.W. Glenny Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports Arch. Intern. Med. 152 1992 1521 1524
105. Y. Takahashi, C. Roman, S. Chemtob, M.M. Tse, E. Lin, M.A. Heymann, and R.I. Clyman Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo Am. J. Physiol Regul. Integr. Comp. Physiol. 278 2000 R1496 R1505
106. M.A. Iniguez, S. Martinez-Martinez, C. Punzon, J.M. Redondo, and M. Fresno An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes J. Biol. Chem. 275 2000 23627 23635
107. M. Sonoshita, K. Takaku, N. Sasaki, Y. Sugimoto, F. Ushikubi, S. Narumiya, M. Oshima, and M.M. Taketo Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(delta 716) knockout mice Nat. Med. 7 2001 1048 1051
108. H. Takeda, M. Sonoshita, H. Oshima, K. Sugihara, P.C. Chulada, R. Langenbach, M. Oshima, and M.M. Taketo Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis Cancer Res. 63 2003 4872 4877
109. E. Gilboa The risk of autoimmunity associated with tumor immunotherapy Nat. Immunol. 2 2001 789 792
110. P. DeLong, T. Tanaka, R. Kruklitis, A.C. Henry, V. Kapoor, L.R. Kaiser, D.H. Sterman, and S.M. Albelda Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy Cancer Res. 63 2003 7845 7852
111. J.L. Marshall, M.J. Hawkins, K.Y. Tsang, E. Richmond, J.E. Pedicano, M.Z. Zhu, and J. Schlom Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen J. Clin. Oncol. 17 1999 332 337
112. M. von Mehren, P. Arlen, K.Y. Tsang, A. Rogatko, N. Meropol, H.S. Cooper, M. Davey, S. McLaughlin, J. Schlom, and L.M. Weiner Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas Clin. Cancer Res. 6 2000 2219 2228
113. J.L. Marshall, R.J. Hoyer, M.A. Toomey, K. Faraguna, P. Chang, E. Richmond, J.E. Pedicano, E. Gehan, R.A. Peck, P. Arlen, K.Y. Tsang, and J. Schlom Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses J. Clin. Oncol. 18 2000 3964 3973
114. F. Guadagni, M. Roselli, M. Cosimelli, A. Spila, F. Cavaliere, R. Arcuri, R. D'Alessandro, P.L. Fracasso, V. Casale, A. Vecchione, C.U. Casciani, J.W. Greiner, and J. Schlom Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation Int. J. Cancer 72 1997 949 954
115. K.M. Sheehan, K. Sheahan, D.P. O'Donoghue, F. MacSweeney, R.M. Conroy, D.J. Fitzgerald, and F.E. Murray The relationship between cyclooxygenase-2 expression and colorectal cancer JAMA 282 1999 1254 1257
116. K. Saukkonen, O. Nieminen, B. van Rees, S. Vilkki, M. Harkonen, M. Juhola, J.P. Mecklin, P. Sipponen, and A. Ristimaki Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma Clin. Cancer Res. 7 2001 1923 1931
117. O.N. Tucker, A.J. Dannenberg, E.K. Yang, F. Zhang, L. Teng, J.M. Daly, R.A. Soslow, J.L. Masferrer, B.M. Woerner, A.T. Koki, and T.J. Fahey III Cyclooxygenase-2 expression is upregulated in human pancreatic cancer Cancer Res. 59 1999 987 990
118. H. Achiwa, Y. Yatabe, T. Hida, T. Kuroishi, K. Kozaki, S. Nakamura, M. Ogawa, T. Sugiura, T. Mitsudomi, and T. Takahashi Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas Clin. Cancer Res. 5 1999 1001 1005
119. S. Kulkarni, J.S. Rader, F. Zhang, H. Liapis, A.T. Koki, J.L. Masferrer, K. Subbaramaiah, and A.J. Dannenberg Cyclooxygenase-2 is overexpressed in human cervical cancer Clin. Cancer Res. 7 2001 429 434
120. G. Chan, J.O. Boyle, E.K. Yang, F. Zhang, P.G. Sacks, J.P. Shah, D. Edelstein, R.A. Soslow, A.T. Koki, B.M. Woerner, J.L. Masferrer, and A.J. Dannenberg Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and neck Cancer Res. 59 1999 991 994
121. S. Mizobata, K. Tompkins, J.F. Simpson, Y. Shyr, and F.J. Primus Induction of cytotoxic T cells and their antitumor activity in mice transgenic for carcinoembryonic antigen Cancer Immunol. Immunother. 49 2000 285 295
122. X. Xu, P. Clarke, G. Szalai, J.E. Shively, L.E. Williams, Y. Shyr, E. Shi, and F.J. Primus Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein Cancer Res. 60 2000 4475 4484
123. R. Xiang, F.J. Primus, J.M. Ruehlmann, A.G. Niethammer, S. Silletti, H.N. Lode, C.S. Dolman, S.D. Gillies, and R.A. Reisfeld A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice J. Immunol. 167 2001 4560 4565
124. R. Xiang, S. Silletti, H.N. Lode, C.S. Dolman, J.M. Ruehlmann, A.G. Niethammer, U. Pertl, S.D. Gillies, F.J. Primus, and R.A. Reisfeld Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice Clin. Cancer Res. 7 2001 856s 864s
125. A.G. Niethammer, R. Xiang, J.C. Becker, H. Wodrich, U. Pertl, G. Karsten, B.P. Eliceiri, and R.A. Reisfeld A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth Nat. Med. 8 2002 1369 1375
126. R. Chakrabarti, Y. Chang, K. Song, and G.J. Prud'homme Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA) Vaccine 22 2004 1199 1205
127. D.W. Grosenbach, J.C. Barrientos, J. Schlom, and J.W. Hodge Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects Cancer Res. 61 2001 4497 4505
128. J.W. Hodge, D.W. Grosenbach, W.M. Aarts, D.J. Poole, and J. Schlom Vaccine therapy of established tumors in the absence of autoimmunity Clin. Cancer Res. 9 2003 1837 1849
129. H. Zhou, Y. Luo, M. Mizutani, N. Mizutani, J.C. Becker, F.J. Primus, R. Xiang, and R.A. Reisfeld A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines J. Clin. Invest. 113 2004 1792 1798
130. E. Reali, D. Canter, H. Zeytin, J. Schlom, and J.W. Greiner Comparative studies of avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms Vaccine 23 2005 2909 2921